FDA Perspectives on Computer Simulations in the Evaluation of Medical Devices

On 29 March 2018, the FDA and Siemens co-organized a webinar on “FDA Perspectives on Computer Simulations in the Evaluation of Medical Devices”. For those of you who missed the webinar, the recorded presentation is available on line.

FDA acknowledges the benefits to public health provided by modeling and simulation, such as those in the developing area of in silico clinical trials; in other words, the use of individualized computer simulation in the development and/or regulatory evaluation of medical products, medical device, or medical interventions (Avicenna Roadmap-2016). FDA advocates for their use as one of many research and product development tools because modeling and simulation play a critical role in organizing diverse data sets, exploring alternate study design strategies, identifying subpopulations for therapy, and in some cases, predicting performance, so that safe and effective new therapeutics can advance more efficiently, from preclinical studies through clinical trials to market.

FDA routinely advises industry on the use of modeling and simulation to predict clinical outcomes, inform clinical trial designs, support evidence of effectiveness, optimize dosing, identify the most relevant patients to study, predict product safety, and evaluate potential adverse event mechanisms. In some cases, in silico clinical trials are used to replace human clinical trials, especially those that are intended to evaluate the risk of drug interactions, or where information from a computer-based model can better inform the performance of a medical device as compared to data collection in a human clinical trial. FDA intends to continue advancing these methodologies and techniques from both a science and regulatory perspective to best take advantage of the benefits for continued product innovation and more rapid introduction of life-saving technology to US patients. This webinar provides an overview of those methodologies and highlight the possibility for in silico clinical trials to be used for evaluating medical products.


  • Tina M. Morrison, Ph.D., Deputy Director, Division of Applied Mechanics, Center for Devices and Radiological Health, U.S. Food and Drug Administration
  • Tom Phillips, Ph.D., Director, Simulation Portfolio Development, Siemens PLM

Full details and the link to the recorded presentation can be found here

Date: 04/04/2018 | Tag: | News: 763 of 1588
All news


More news


More events

Subscribe to the VPH Institute Newsletter


Read all the newsletters of the VPH Institute